Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.72 |
| ▸ | DGKA | P23743 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026965 | 0.96 | DNM1 (0.73) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL25761527 | 0.94 | DNM1 (0.71) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL8442490 | 0.93 | DNM1 (0.79) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL5179416 | 0.93 | DNM1 (0.79) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL5178920 | 0.93 | DNM1 (0.79) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL7035299 | 0.93 | DNM1 (0.79) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL20149658 | 0.92 | DNM1 (0.64) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL25125901 | 0.91 | DNM1 (0.71) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL17367539 | 0.91 | DNM1 (0.71) | DNM1DGKANAAAPRSS1PRSS2 | |
| SCHEMBL17367563 | 0.91 | DNM1 (0.71) | DNM1DGKANAAAPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2025-05-22 | — | — | US | claimed |
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-26 | — | — | US | claimed |
| EP-3538515-B1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2022-07-20 | — | — | EP | claimed |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | claimed |
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2025-05-22 | — | — | US | disclosed |
| US-20240246898-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-25 | — | — | US | disclosed |
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-26 | — | — | US | disclosed |
| EP-3538515-B1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2022-07-20 | — | — | EP | disclosed |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| WO-2018087753-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | NPC1L1, NPC1, CETP | DNM1 165/4885DGKA 602/4885NAAA 593/4885 |
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | DNM1 165/4885DGKA 602/4885NAAA 593/4885 |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | DNM1 165/4885DGKA 602/4885NAAA 593/4885 |
| US-20240246898-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | DNM1 165/4885DGKA 602/4885NAAA 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.